Results

1–10 of 27 results for Bevacizumab

Cost-Effectiveness of Aflibercept Monotherapy vs Bevacizumab-First Followed by Switching to Aflibercept if Needed for Diabetic Macular Edema
Mathew W. MacCumber, MD, PhD
Annual Meeting Talks
2023
Subretinal Aflibercept vs Ranibizumab vs Bevacizumab in the Context of PPV: Pneumatic Displacement With Subretinal Air and tPA in Naïve Submacular Hemorrhage Due to nAMD
Matias Iglicki, MD
Annual Meeting Talks
2024
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2022
Clinical Features and Outcomes of Infants With Retinopathy of Prematurity Who Fail Anti-VEGF Therapy (FELLOWS FORUM AWARD WINNER)
Lucy T Xu, MD
Annual Meeting Talks
2021
Computerized Analysis of Retinal Vascular Growth Following Intravitreal Bevacizumab Monotherapy in Retinopathy of Prematurity Until Three Years of Age
Swati Agarwal-Sinha, MD, FASRS
Annual Meeting Talks
2021
Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients With Wet AMD, DME, and BRVO
Suber S. Huang, MD, MBA, FASRS
Annual Meeting Talks
2021
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Updates from the Field
2022
Low Incidence of Endopthalmitis After Intravitreal Injections in an Office Setting Without Gloves and Drapes With a Modified Technique
Kamal Kishore, MD, MBBS
On Demand Cases, Courses, and Papers
2020
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020
Adjunctive Focal Laser Following Central Fluid Resolution After Bevacizumab, Ranibizumab, or Aflibercept Injection: A Secondary Analysis of Protocol T
Jennifer R Gallagher, MD
Annual Meeting Talks
2020